Wearable technology and digital health specialist Activinsights has announced a partnership agreement with the cardiovascular research organisation Cardialysis to promote the use of remote monitoring wearables as a tool for researchers to better understand the daily lifestyles of cardiac patients.
Using Activinsights’ wearable devices, Cardialysis will monitor behaviours such as sleep, sedentary behaviour, walking and high activity levels, as related to cardiology. By collecting in-depth raw data, sponsors will be able to analyse and understand how certain treatments and interventions may be affecting the patient, Activinsighsts and Cardialysis said in a press release.
Ernest Spitzer, chief medical officer at Cardialysis, commented: “The use of professional wearables in clinical research brings us a step closer to understanding how new therapies effect the day-to-day symptoms of trial participants. As much as traditional clinical outcomes remain a priority for effectiveness and safety assessments, incorporating actigraphy into clinical research may become a new standard for the short and mid-term evaluation of cardiovascular therapies.”
Three conditions where the use of actigraphy becomes immediately evident are heart failure, structural heart disease, and coronary artery disease, especially in comparisons between surgical and transcatheter interventions, commented Spitzer.
Bill Hogan, Activinsights’ CEO, added: “We are very excited about this collaboration. The opportunity to work with Cardialysis to offer our professional wearables will be of huge value to clinicians and researchers as they assess patient behaviours. With the move towards decentralised trials accelerating, patient remote monitoring is now critical, particularly for long-term deployment, so this relationship will be significant to cardiology patients going forward.”
The partnership supports trials in gaining additional objective digital measures outside of the clinical environment, the press release adds, going on to state that the ability to understand a patient’s quality of life remotely, along with supporting clinical endpoints such as the six-minute walk test in a free-living environment, will continue to innovate the market.
